{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T14:22:52Z","timestamp":1783002172028,"version":"3.54.5"},"reference-count":153,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Hematology"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1053\/j.seminhematol.2024.08.002","type":"journal-article","created":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T20:34:48Z","timestamp":1724445288000},"page":"321-332","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["The winding road: Infectious disease considerations for CAR-T and other novel adoptive cellular therapies in the era of COVID-19"],"prefix":"10.1053","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6620-6920","authenticated-orcid":false,"given":"Kanal","family":"Singh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph M.","family":"Rocco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronique","family":"Nussenblatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"25","key":"10.1053\/j.seminhematol.2024.08.002_bib0001","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1056\/NEJM198812223192527","article-title":"Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report","volume":"319","author":"Rosenberg","year":"1988","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.08.002_bib0002","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1182\/blood-2017-07-793760","article-title":"Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy","volume":"131","author":"Hill","year":"2018","journal-title":"Blood"},{"issue":"23","key":"10.1053\/j.seminhematol.2024.08.002_bib0003","doi-asserted-by":"crossref","first-page":"5312","DOI":"10.1182\/bloodadvances.2021004896","article-title":"Infectious complications of CAR T-cell therapy across novel antigen targets in the first 30 days","volume":"5","author":"Mikkilineni","year":"2021","journal-title":"Blood Adv"},{"issue":"2","key":"10.1053\/j.seminhematol.2024.08.002_bib0004","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/s41409-021-01483-8","article-title":"Defining the impact of SARS-COV-2 on delivery of CAR T-cell therapy in Europe: a retrospective survey from the CTIWP of the EBMT","volume":"57","author":"Ghorashian","year":"2022","journal-title":"Bone Marrow Transplantat"},{"issue":"12","key":"10.1053\/j.seminhematol.2024.08.002_bib0005","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1080\/10428194.2023.2248329","article-title":"Improved COVID-19 outcomes in CAR-T patients in the age of vaccination and preemptive pharmacotherapeutics","volume":"64","author":"Cheok","year":"2023","journal-title":"Leukem Lymph"},{"issue":"27","key":"10.1053\/j.seminhematol.2024.08.002_bib0006","doi-asserted-by":"crossref","first-page":"878","DOI":"10.15585\/mmwr.mm7127a3","article-title":"Factors associated with severe outcomes among immunocompromised adults hospitalized for COVID-19 - COVID-NET, 10 States, March 2020-February 2022","volume":"71","author":"Singson","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1053\/j.seminhematol.2024.08.002_bib0007","unstructured":"COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. National Institutes of Health. Available at https:\/\/wayback.archive-it.org\/4887\/20240626155208\/, https:\/\/www.covid19treatmentguidelines.nih.gov\/. Accessed [29.05.24]."},{"issue":"12","key":"10.1053\/j.seminhematol.2024.08.002_bib0008","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.jtct.2022.09.002","article-title":"Revised guidelines for coronavirus disease 19 management in hematopoietic cell transplantation and cellular therapy recipients (August 2022)","volume":"28","author":"Dioverti","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"12","key":"10.1053\/j.seminhematol.2024.08.002_bib0009","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1182\/blood-2011-10-384388","article-title":"B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells","volume":"119","author":"Kochenderfer","year":"2012","journal-title":"Blood"},{"issue":"26","key":"10.1053\/j.seminhematol.2024.08.002_bib0010","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","article-title":"Chimeric antigen receptor T cells in refractory B-Cell lymphomas","volume":"377","author":"Schuster","year":"2017","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1053\/j.seminhematol.2024.08.002_bib0011","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-Cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2024.08.002_bib0012","unstructured":"Food and Drug Administration. Ciltacabtagene autoleucel (CARVYKTI) [package insert]. 2024. Available at: https:\/\/www.fda.gov\/media\/156560\/download. [accessed 30.05.24]."},{"key":"10.1053\/j.seminhematol.2024.08.002_bib0013","unstructured":"Food and Drug Administration. Idecabtagene vicleucel (ABECMA) [package insert]. 2024. Available at: https:\/\/www.fda.gov\/media\/147055\/download. [accessed 05.08.24]."},{"issue":"20","key":"10.1053\/j.seminhematol.2024.08.002_bib0014","doi-asserted-by":"crossref","first-page":"6106","DOI":"10.1158\/1078-0432.CCR-06-1183","article-title":"A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer","volume":"12","author":"Kershaw","year":"2006","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.08.002_bib0015","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/s41571-023-00832-4","article-title":"CAR T cell therapy for patients with solid tumours: key lessons to learn and unlearn","volume":"21","author":"Albelda","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"issue":"6","key":"10.1053\/j.seminhematol.2024.08.002_bib0016","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/s41571-020-00456-y","article-title":"Beyond the storm - subacute toxicities and late effects in children receiving CAR T cells","volume":"18","author":"Shalabi","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"issue":"7","key":"10.1053\/j.seminhematol.2024.08.002_bib0017","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtct.2023.03.006","article-title":"Immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome","volume":"29","author":"Hines","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"10","key":"10.1053\/j.seminhematol.2024.08.002_bib0018","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1182\/blood.2023020578","article-title":"Immune effector cell-associated hematotoxicity: EHA\/EBMT consensus grading and best practice recommendations","volume":"142","author":"Rejeski","year":"2023","journal-title":"Blood"},{"issue":"6","key":"10.1053\/j.seminhematol.2024.08.002_bib0019","doi-asserted-by":"crossref","first-page":"e459","DOI":"10.1016\/S2352-3026(24)00077-2","article-title":"Immune effector cell-associated haematotoxicity after CAR T-cell therapy: from mechanism to management","volume":"11","author":"Rejeski","year":"2024","journal-title":"Lancet Haematol"},{"issue":"10","key":"10.1053\/j.seminhematol.2024.08.002_bib0020","doi-asserted-by":"crossref","first-page":"2346","DOI":"10.1200\/JCO.2005.00.240","article-title":"Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma","volume":"23","author":"Dudley","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2024.08.002_bib0021","unstructured":"Food and Drug Administration. Lifileucel (Amtagvi) [package insert]. 2024. Available at: https:\/\/www.fda.gov\/media\/176417\/download [accessed 15.05.24]."},{"issue":"24","key":"10.1053\/j.seminhematol.2024.08.002_bib0022","doi-asserted-by":"crossref","first-page":"2656","DOI":"10.1200\/JCO.21.00612","article-title":"Lifileucel, a tumor-infiltrating lymphocyte therapy, in metastatic melanoma","volume":"39","author":"Sarnaik","year":"2021","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1053\/j.seminhematol.2024.08.002_sbref0023","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005755","volume":"10","author":"Chesney","year":"2022","journal-title":"J Immunother Cancer"},{"issue":"23","key":"10.1053\/j.seminhematol.2024.08.002_bib0024","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1056\/NEJMoa2210233","article-title":"Tumor-infiltrating lymphocyte therapy or ipilimumab in advanced melanoma","volume":"387","author":"Rohaan","year":"2022","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1053\/j.seminhematol.2024.08.002_bib0025","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1158\/1078-0432.CCR-18-2722","article-title":"A phase ii study of tumor-infiltrating lymphocyte therapy for human papillomavirus-associated epithelial cancers","volume":"25","author":"Stevanovi\u0107","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1053\/j.seminhematol.2024.08.002_bib0026","doi-asserted-by":"crossref","DOI":"10.4161\/23723556.2014.976507","article-title":"Phase I trial of adoptively transferred tumor-infiltrating lymphocyte immunotherapy following concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma","volume":"4","author":"Li","year":"2015","journal-title":"Oncoimmunology"},{"key":"10.1053\/j.seminhematol.2024.08.002_bib0027","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2023.112965","article-title":"A phase II randomised controlled trial of adjuvant tumour-infiltrating lymphocytes for pretreatment Epstein-Barr virus DNA-selected high-risk nasopharyngeal carcinoma patients","volume":"191","author":"Liang","year":"2023","journal-title":"Eur J Cancer"},{"issue":"10","key":"10.1053\/j.seminhematol.2024.08.002_bib0028","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/s00262-002-0315-1","article-title":"Randomized trial of adoptive transfer of melanoma tumor-infiltrating lymphocytes as adjuvant therapy for stage III melanoma","volume":"51","author":"Dr\u00e9no","year":"2002","journal-title":"Cancer Immunol Immunother"},{"issue":"6","key":"10.1053\/j.seminhematol.2024.08.002_bib0029","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/S1470-2045(17)30251-6","article-title":"Treatment of metastatic uveal melanoma with adoptive transfer of tumour-infiltrating lymphocytes: a single-centre, two-stage, single-arm, phase 2 study","volume":"18","author":"Chandran","year":"2017","journal-title":"Lancet Oncol"},{"issue":"17","key":"10.1053\/j.seminhematol.2024.08.002_bib0030","doi-asserted-by":"crossref","first-page":"4792","DOI":"10.1158\/1078-0432.CCR-13-0380","article-title":"Adoptive transfer of tumor-infiltrating lymphocytes in patients with metastatic melanoma: intent-to-treat analysis and efficacy after failure to prior immunotherapies","volume":"19","author":"Besser","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.seminhematol.2024.08.002_bib0031","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1018962","article-title":"Tumor-infiltrating lymphocytes for treatment of solid tumors: it takes two to tango?","volume":"13","author":"Kazemi","year":"2022","journal-title":"Front Immunol"},{"issue":"24","key":"10.1053\/j.seminhematol.2024.08.002_bib0032","doi-asserted-by":"crossref","first-page":"6758","DOI":"10.1158\/1078-0432.CCR-12-1177","article-title":"Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients","volume":"18","author":"Radvanyi","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"8","key":"10.1053\/j.seminhematol.2024.08.002_bib0033","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1038\/s41591-021-01462-y","article-title":"Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial","volume":"27","author":"Creelan","year":"2021","journal-title":"Nat Med"},{"issue":"12","key":"10.1053\/j.seminhematol.2024.08.002_bib0034","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1093\/annonc\/mdz398","article-title":"Efficacy of adoptive therapy with tumor-infiltrating lymphocytes and recombinant interleukin-2 in advanced cutaneous melanoma: a systematic review and meta-analysis","volume":"30","author":"Dafni","year":"2019","journal-title":"Ann Oncol"},{"issue":"12","key":"10.1053\/j.seminhematol.2024.08.002_bib0035","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1038\/s41573-023-00809-z","article-title":"T cell receptor therapeutics: immunological targeting of the intracellular cancer proteome","volume":"22","author":"Klebanoff","year":"2023","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.08.002_bib0036","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.ccell.2022.10.016","article-title":"Engineered T cell therapy for viral and non-viral epithelial cancers","volume":"41","author":"Norberg","year":"2023","journal-title":"Cancer Cell"},{"key":"10.1053\/j.seminhematol.2024.08.002_bib0037","unstructured":"Food and Drug Administration. Afamitresgene autoleucel (TECELRA) [package insert]. 2024. Available at: https:\/\/www.fda.gov\/media\/180565\/download. [accessed 08.08.24]."},{"issue":"7","key":"10.1053\/j.seminhematol.2024.08.002_bib0038","doi-asserted-by":"crossref","first-page":"eadf3700","DOI":"10.1126\/sciadv.adf3700","article-title":"TCR-engineered T cell therapy in solid tumors: state of the art and perspectives","volume":"9","author":"Baulu","year":"2023","journal-title":"Sci Adv"},{"key":"10.1053\/j.seminhematol.2024.08.002_bib0039","unstructured":"Food and Drug Administration. Aldesleukin (PROLEUKIN) [package insert]. 2023. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/103293s51,54lbl.pdf [accessed 05.08.24]."},{"issue":"10","key":"10.1053\/j.seminhematol.2024.08.002_bib0040","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.jtct.2022.06.025","article-title":"The next generation of cellular immunotherapy: chimeric antigen receptor-natural killer cells","volume":"28","author":"Moscarelli","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"6","key":"10.1053\/j.seminhematol.2024.08.002_bib0041","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1910607","article-title":"Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors","volume":"382","author":"Liu","year":"2020","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1053\/j.seminhematol.2024.08.002_bib0042","first-page":"1083","article-title":"First-in-man clinical trial of CAR NK-92 cells: safety test of CD33-CAR NK-92 cells in patients with relapsed and refractory acute myeloid leukemia","volume":"8","author":"Tang","year":"2018","journal-title":"Am J Cancer Res"},{"issue":"6","key":"10.1053\/j.seminhematol.2024.08.002_bib0043","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1016\/j.ymthe.2019.03.011","article-title":"Adoptive transfer of NKG2D CAR mRNA-engineered natural killer cells in colorectal cancer patients","volume":"27","author":"Xiao","year":"2019","journal-title":"Mol Ther"},{"issue":"5","key":"10.1053\/j.seminhematol.2024.08.002_bib0044","doi-asserted-by":"crossref","first-page":"ofaa121","DOI":"10.1093\/ofid\/ofaa121","article-title":"Infectious complications following CD19 chimeric antigen receptor T-cell therapy for children, adolescents, and young adults","volume":"7","author":"Vora","year":"2020","journal-title":"Open Forum Infect Dis"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.08.002_bib0045","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1182\/bloodadvances.2020002732","article-title":"Immune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B-cell lymphoma","volume":"5","author":"Baird","year":"2021","journal-title":"Blood Adv"},{"issue":"18","key":"10.1053\/j.seminhematol.2024.08.002_bib0046","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-Cell therapy bb2121 in relapsed or refractory multiple myeloma","volume":"380","author":"Raje","year":"2019","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1053\/j.seminhematol.2024.08.002_bib0047","doi-asserted-by":"crossref","first-page":"978","DOI":"10.3324\/haematol.2019.238634","article-title":"Immune reconstitution and associated infections following axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma","volume":"106","author":"Logue","year":"2021","journal-title":"Haematologica"},{"issue":"23","key":"10.1053\/j.seminhematol.2024.08.002_bib0048","doi-asserted-by":"crossref","first-page":"5290","DOI":"10.1182\/bloodadvances.2021004603","article-title":"Humoral immune reconstitution after anti-BCMA CAR T-cell therapy in relapsed\/refractory multiple myeloma","volume":"5","author":"Wang","year":"2021","journal-title":"Blood Adv"},{"issue":"3","key":"10.1053\/j.seminhematol.2024.08.002_bib0049","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1182\/blood-2016-01-694356","article-title":"Persistence of long-lived plasma cells and humoral immunity in individuals responding to CD19-directed CAR T-cell therapy","volume":"128","author":"Bhoj","year":"2016","journal-title":"Blood"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.08.002_bib0050","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.bbmt.2019.08.003","article-title":"Late events after treatment with CD19-targeted chimeric antigen receptor modified T cells","volume":"26","author":"Cordeiro","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.08.002_bib0051","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.jaci.2010.04.016","article-title":"Recurrent and persistent respiratory tract viral infections in patients with primary hypogammaglobulinemia","volume":"126","author":"Kainulainen","year":"2010","journal-title":"J Allergy Clin Immunol"},{"issue":"14","key":"10.1053\/j.seminhematol.2024.08.002_bib0052","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1200\/JCO.2014.58.9093","article-title":"Complete regression of metastatic cervical cancer after treatment with human papillomavirus-targeted tumor-infiltrating T cells","volume":"33","author":"Stevanovi\u0107","year":"2015","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1053\/j.seminhematol.2024.08.002_bib0053","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1182\/bloodadvances.2021005616","article-title":"COVID-19 and CAR T cells: a report on current challenges and future directions from the EPICOVIDEHA survey by EHA-IDWP","volume":"6","author":"Busca","year":"2022","journal-title":"Blood Advances"},{"issue":"12","key":"10.1053\/j.seminhematol.2024.08.002_bib0054","doi-asserted-by":"crossref","first-page":"3585","DOI":"10.1038\/s41375-021-01466-0","volume":"35","author":"Spanjaart","year":"2021","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2024.08.002_bib0055","unstructured":"World Health Organization. Coronavirus novel. 2019. Situation Rep. Available at: https:\/\/www.who.int\/emergencies\/diseases\/novel-coronavirus-2019\/situation-reports. [accessed 15.05.24]."},{"issue":"12","key":"10.1053\/j.seminhematol.2024.08.002_bib0056","doi-asserted-by":"crossref","first-page":"6656","DOI":"10.1172\/JCI141777","article-title":"Favorable outcomes of COVID-19 in recipients of hematopoietic cell transplantation","volume":"130","author":"Shah","year":"2020","journal-title":"J Clin Investigat"},{"issue":"2","key":"10.1053\/j.seminhematol.2024.08.002_sbref0057","volume":"10","author":"Ljungman","year":"2023","journal-title":"Open Forum Infect Dis"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.08.002_bib0058","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtct.2023.09.027","article-title":"Outcomes and management of the SARS-CoV2 omicron variant in recipients of hematopoietic cell transplantation and chimeric antigen receptor T Cell therapy","volume":"30","author":"Infante","year":"2024","journal-title":"Transplant Cell Ther"},{"issue":"22","key":"10.1053\/j.seminhematol.2024.08.002_bib0059","doi-asserted-by":"crossref","first-page":"20838","DOI":"10.1002\/cam4.6657","article-title":"Outcomes and risk factors of SARS-CoV-2 omicron variant in B-cell lymphoma patients following CD19 targeted CAR-T therapy","volume":"12","author":"Xiao","year":"2023","journal-title":"Cancer Med"},{"issue":"4","key":"10.1053\/j.seminhematol.2024.08.002_bib0060","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s40472-022-00385-y","article-title":"Immunocompromised patients with protracted COVID-19: a review of \"long persisters\"","volume":"9","author":"Dioverti","year":"2022","journal-title":"Curr Transplant Rep"},{"issue":"22","key":"10.1053\/j.seminhematol.2024.08.002_bib0061","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1001\/jama.2023.8823","article-title":"Development of a definition of postacute sequelae of SARS-CoV-2 infection","volume":"329","author":"Thaweethai","year":"2023","journal-title":"Jama"},{"key":"10.1053\/j.seminhematol.2024.08.002_bib0062","doi-asserted-by":"crossref","DOI":"10.1016\/S1473-3099(23)00815-0","article-title":"Persistent SARS-CoV-2 infection: significance and implications","author":"Machkovech","year":"2024","journal-title":"Lancet Infect Dis"},{"issue":"11","key":"10.1053\/j.seminhematol.2024.08.002_bib0063","doi-asserted-by":"crossref","first-page":"ofab217","DOI":"10.1093\/ofid\/ofab217","article-title":"The longest persistence of viable SARS-CoV-2 with recurrence of viremia and relapsing symptomatic COVID-19 in an immunocompromised patient-a case study","volume":"8","author":"Sepulcri","year":"2021","journal-title":"Open Forum Infect Dis"},{"issue":"7","key":"10.1053\/j.seminhematol.2024.08.002_bib0064","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1093\/infdis\/jiab622","article-title":"Yearlong COVID-19 infection reveals within-host evolution of SARS-CoV-2 in a patient with B-Cell depletion","volume":"225","author":"Nussenblatt","year":"2021","journal-title":"J Infect Dis"},{"issue":"2","key":"10.1053\/j.seminhematol.2024.08.002_bib0065","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1093\/cid\/ciad494","article-title":"Nirmatrelvir resistance-de novo E166V\/L50V mutations in an immunocompromised patient treated with prolonged nirmatrelvir\/ritonavir monotherapy leading to clinical and virological treatment failure-a case report","volume":"78","author":"Zuckerman","year":"2024","journal-title":"Clin Infect Dis"},{"issue":"7","key":"10.1053\/j.seminhematol.2024.08.002_bib0066","doi-asserted-by":"crossref","first-page":"e1762","DOI":"10.1093\/cid\/ciaa1474","article-title":"Emerging RNA-dependent RNA polymerase mutation in a remdesivir-treated B-cell immunodeficient patient with protracted coronavirus disease 2019","volume":"73","author":"Martinot","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"7853","key":"10.1053\/j.seminhematol.2024.08.002_bib0067","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/s41586-021-03291-y","article-title":"SARS-CoV-2 evolution during treatment of chronic infection","volume":"592","author":"Kemp","year":"2021","journal-title":"Nature"},{"issue":"23","key":"10.1053\/j.seminhematol.2024.08.002_bib0068","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1056\/NEJMoa2101544","article-title":"Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19","volume":"384","author":"Sadoff","year":"2021","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1053\/j.seminhematol.2024.08.002_bib0069","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N Engl J Med"},{"issue":"27","key":"10.1053\/j.seminhematol.2024.08.002_bib0070","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1053\/j.seminhematol.2024.08.002_bib0071","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1111\/bjh.17818","article-title":"Safety and antibody response after one and\/or two doses of BNT162b2 Anti-SARS-CoV-2 mRNA vaccine in patients treated by CAR T cells therapy","volume":"196","author":"Gastinne","year":"2022","journal-title":"Br J Haematol"},{"issue":"6","key":"10.1053\/j.seminhematol.2024.08.002_bib0072","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.clml.2023.03.002","article-title":"Response to COVID-19 vaccination post-CAR T therapy in patients with non-hodgkin lymphoma and multiple myeloma","volume":"23","author":"Wiedmeier-Nutor","year":"2023","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"14","key":"10.1053\/j.seminhematol.2024.08.002_bib0073","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1182\/blood.2021012769","article-title":"Response to SARS-CoV-2 vaccination in patients after hematopoietic cell transplantation and CAR T-cell therapy","volume":"138","author":"Dhakal","year":"2021","journal-title":"Blood"},{"issue":"10","key":"10.1053\/j.seminhematol.2024.08.002_bib0074","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1182\/bloodadvances.2022007806","article-title":"Cellular and humoral immune responses to SARS-CoV-2 vaccination in patients after CD19.CAR T-cell therapy","volume":"7","author":"Reimann","year":"2023","journal-title":"Blood Adv"},{"issue":"4","key":"10.1053\/j.seminhematol.2024.08.002_bib0075","doi-asserted-by":"crossref","first-page":"118","DOI":"10.15585\/mmwr.mm7104a2","article-title":"Effectiveness of a third dose of Pfizer-BioNTech and moderna vaccines in preventing COVID-19 hospitalization among immunocompetent and immunocompromised adults - United States, August-December 2021","volume":"71","author":"Tenforde","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"3","key":"10.1053\/j.seminhematol.2024.08.002_bib0076","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.jtct.2023.12.011","article-title":"Efficacy of multiple SARS-CoV-2 vaccine doses in patients with B Cell hematologic malignancies receiving chimeric antigen receptor T cell therapy: a contemporary cohort analysis","volume":"30","author":"Abid","year":"2024","journal-title":"Transplant Cell Ther"},{"issue":"6","key":"10.1053\/j.seminhematol.2024.08.002_bib0077","doi-asserted-by":"crossref","first-page":"398.e1","DOI":"10.1016\/j.jtct.2023.03.005","article-title":"Severe acute respiratory syndrome coronavirus 2 vaccine immunogenicity among chimeric antigen receptor T Cell therapy recipients","volume":"29","author":"Aleissa","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"11","key":"10.1053\/j.seminhematol.2024.08.002_bib0078","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1038\/s41409-022-01795-3","article-title":"Efficacy of SARS-CoV-2 primary and booster vaccine doses in CAR-T recipients \u2013 targeting the target antigen","volume":"57","author":"Uyemura","year":"2022","journal-title":"Bone Marrow Transplantat"},{"issue":"2","key":"10.1053\/j.seminhematol.2024.08.002_bib0079","doi-asserted-by":"crossref","first-page":"381","DOI":"10.3201\/eid2902.221422","article-title":"Correlates of protection, thresholds of protection, and immunobridging among persons with SARS-CoV-2 infection","volume":"29","author":"Khoury","year":"2023","journal-title":"Emerg Infect Dis"},{"issue":"18","key":"10.1053\/j.seminhematol.2024.08.002_bib0080","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1001\/jama.2021.18919","article-title":"The flawed science of antibody testing for SARS-CoV-2 immunity","volume":"326","author":"Abbasi","year":"2021","journal-title":"JAMA"},{"issue":"2","key":"10.1053\/j.seminhematol.2024.08.002_bib0081","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1182\/blood.2022016166","article-title":"Enhanced BNT162b2 vaccine-induced cellular immunity in anti-CD19 CAR T cell-treated patients","volume":"140","author":"Oh","year":"2022","journal-title":"Blood"},{"issue":"9","key":"10.1053\/j.seminhematol.2024.08.002_bib0082","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/j.jtct.2021.06.024","article-title":"Safety and immunogenicity of the BNT162b2 mRNA COVID-19 vaccine in patients after allogeneic HCT or CD19-based CART therapy\u2014a single-center prospective cohort study","volume":"27","author":"Ram","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"3","key":"10.1053\/j.seminhematol.2024.08.002_bib0083","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.jtct.2024.02.004","article-title":"When four is more \u2013 improved COVID-19 antibody responses with 4 doses of vaccine in CAR T-cell therapy recipients","volume":"30","author":"Hall","year":"2024","journal-title":"Transplant Cell Ther"},{"key":"10.1053\/j.seminhematol.2024.08.002_bib0084","unstructured":"Centers for Disease Control and Prevention. COVID-19 vaccines for people who are moderately or severely immunocompromised. 2024. Available at: https:\/\/www.cdc.gov\/vaccines\/covid-19\/clinical-considerations\/interim-considerations-us.html#immunocompromised. [accessed 15.05.24]"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.08.002_bib0085","doi-asserted-by":"crossref","first-page":"10-8","DOI":"10.1016\/j.jtct.2022.10.010","volume":"29","author":"Khawaja","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"6","key":"10.1053\/j.seminhematol.2024.08.002_bib0086","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1038\/s41577-021-00542-x","article-title":"Neutralizing monoclonal antibodies for treatment of COVID-19","volume":"21","author":"Taylor","year":"2021","journal-title":"Nat Rev Immunol"},{"key":"10.1053\/j.seminhematol.2024.08.002_bib0087","unstructured":"Food and Drug Administration. Emergency use authorization 122: Emergency use of PEMGARDA (pemivibart) for the pre-exposure prophylaxis of coronavirus disease 2019 (COVID-19). Available at: https:\/\/www.fda.gov\/media\/177068\/download. [accessed 15.05.24]."},{"issue":"6","key":"10.1053\/j.seminhematol.2024.08.002_sbref0088","volume":"10","author":"Ison","year":"2023","journal-title":"Open Forum Infect Dis"},{"issue":"7","key":"10.1053\/j.seminhematol.2024.08.002_bib0089","doi-asserted-by":"crossref","first-page":"e250","DOI":"10.1093\/cid\/ciac724","article-title":"Infectious diseases society of America guidelines on the treatment and management of patients with COVID-19 (September 2022)","volume":"78","author":"Bhimraj","year":"2022","journal-title":"Clin Infect Dis"},{"issue":"15","key":"10.1053\/j.seminhematol.2024.08.002_bib0090","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1056\/NEJMoa2118542","article-title":"Oral nirmatrelvir for high-risk, nonhospitalized adults with covid-19","volume":"386","author":"Hammond","year":"2022","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1053\/j.seminhematol.2024.08.002_bib0091","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1056\/NEJMoa2116846","article-title":"Early remdesivir to prevent progression to severe Covid-19 in outpatients","volume":"386","author":"Gottlieb","year":"2022","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1053\/j.seminhematol.2024.08.002_bib0092","doi-asserted-by":"crossref","first-page":"e342","DOI":"10.1093\/cid\/ciac443","article-title":"Effectiveness of paxlovid in reducing severe coronavirus disease 2019 and mortality in high-risk patients","volume":"76","author":"Najjar-Debbiny","year":"2023","journal-title":"Clin Infect Dis"},{"key":"10.1053\/j.seminhematol.2024.08.002_bib0093","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.101939","article-title":"Nirmatrelvir\/ritonavir in COVID-19 patients with haematological malignancies: a report from the EPICOVIDEHA registry","volume":"58","author":"Salmanton-Garc\u00eda","year":"2023","journal-title":"EClinicalMedicine"},{"issue":"10","key":"10.1053\/j.seminhematol.2024.08.002_bib0094","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.36678","article-title":"Nirmatrelvir-ritonavir and COVID-19 mortality and hospitalization among patients with vulnerability to COVID-19 complications","volume":"6","author":"Dormuth","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"12","key":"10.1053\/j.seminhematol.2024.08.002_bib0095","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1093\/cid\/ciad460","article-title":"Remdesivir reduced mortality in immunocompromised patients hospitalized for COVID-19 across variant waves: findings from routine clinical practice","volume":"77","author":"Mozaffari","year":"2023","journal-title":"Clin Infect Dis"},{"issue":"6","key":"10.1053\/j.seminhematol.2024.08.002_bib0096","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1056\/NEJMoa2116044","article-title":"Molnupiravir for oral treatment of Covid-19 in nonhospitalized patients","volume":"386","author":"Jayk Bernal","year":"2022","journal-title":"N Engl J Med"},{"issue":"10373","key":"10.1053\/j.seminhematol.2024.08.002_bib0097","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0140-6736(22)02597-1","article-title":"Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial","volume":"401","author":"Butler","year":"2023","journal-title":"Lancet"},{"issue":"3","key":"10.1053\/j.seminhematol.2024.08.002_bib0098","doi-asserted-by":"crossref","first-page":"e26","DOI":"10.1093\/cid\/ciac687","article-title":"Impact of the use of oral antiviral agents on the risk of hospitalization in community coronavirus disease 2019 patients (COVID-19)","volume":"76","author":"Yip","year":"2023","journal-title":"Clin Infect Dis"},{"issue":"5","key":"10.1053\/j.seminhematol.2024.08.002_bib0099","doi-asserted-by":"crossref","first-page":"e452","DOI":"10.1016\/S2666-5247(23)00393-2","article-title":"Effect of molnupiravir on SARS-CoV-2 evolution in immunocompromised patients: a retrospective observational study","volume":"5","author":"Fountain-Jones","year":"2024","journal-title":"Lancet Microbe"},{"issue":"2","key":"10.1053\/j.seminhematol.2024.08.002_bib0100","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.54991","article-title":"Efficacy and safety of 5-day oral ensitrelvir for patients with mild to moderate COVID-19: the SCORPIO-SR randomized clinical trial","volume":"7","author":"Yotsuyanagi","year":"2024","journal-title":"JAMA Network Open"},{"issue":"2","key":"10.1053\/j.seminhematol.2024.08.002_bib0101","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S1473-3099(23)00577-7","article-title":"Oral VV116 versus placebo in patients with mild-to-moderate COVID-19 in China: a multicentre, double-blind, phase 3, randomised controlled study","volume":"24","author":"Fan","year":"2024","journal-title":"Lancet Infect Dis"},{"issue":"8","key":"10.1053\/j.seminhematol.2024.08.002_bib0102","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1056\/NEJMoa2021436","article-title":"Dexamethasone in hospitalized patients with Covid-19","volume":"384","author":"Horby","year":"2021","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.08.002_bib0103","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02532-2021","article-title":"Dexamethasone in hospitalised COVID-19 patients not on intensive respiratory support","volume":"60","author":"Crothers","year":"2022","journal-title":"Eur Respir J"},{"issue":"19","key":"10.1053\/j.seminhematol.2024.08.002_bib0104","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa2007764","article-title":"Remdesivir for the treatment of Covid-19 - final report","volume":"383","author":"Beigel","year":"2020","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1053\/j.seminhematol.2024.08.002_bib0105","doi-asserted-by":"crossref","first-page":"E242","DOI":"10.1503\/cmaj.211698","article-title":"Remdesivir for the treatment of patients in hospital with COVID-19 in Canada: a randomized controlled trial","volume":"194","author":"Ali","year":"2022","journal-title":"Cmaj"},{"issue":"10339","key":"10.1053\/j.seminhematol.2024.08.002_bib0106","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1016\/S0140-6736(22)00519-0","article-title":"Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO solidarity randomised trial and updated meta-analyses","volume":"399","year":"2022","journal-title":"Lancet"},{"issue":"16","key":"10.1053\/j.seminhematol.2024.08.002_bib0107","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1056\/NEJMoa2100433","article-title":"Interleukin-6 receptor antagonists in critically Ill patients with covid-19","volume":"384","author":"Gordon","year":"2021","journal-title":"N Engl J Med"},{"issue":"10285","key":"10.1053\/j.seminhematol.2024.08.002_bib0108","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1016\/S0140-6736(21)00676-0","article-title":"Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial","volume":"397","year":"2021","journal-title":"Lancet"},{"issue":"12","key":"10.1053\/j.seminhematol.2024.08.002_bib0109","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1016\/S2213-2600(21)00331-3","article-title":"Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial","volume":"9","author":"Marconi","year":"2021","journal-title":"Lancet Respir Med"},{"issue":"4","key":"10.1053\/j.seminhematol.2024.08.002_bib0110","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1001\/jama.2023.11043","article-title":"Abatacept, cenicriviroc, or infliximab for treatment of adults hospitalized with COVID-19 pneumonia: a randomized clinical trial","volume":"330","author":"O'Halloran","year":"2023","journal-title":"Jama"},{"issue":"7","key":"10.1053\/j.seminhematol.2024.08.002_bib0111","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1515\/cclm-2020-0188","article-title":"Prominent changes in blood coagulation of patients with SARS-CoV-2 infection","volume":"58","author":"Han","year":"2020","journal-title":"Clin Chem Lab Med"},{"key":"10.1053\/j.seminhematol.2024.08.002_sbref0112","article-title":"Infectious diseases society of america guidelines on the diagnosis of COVID-19: serologic testing","author":"Hayden","year":"2024","journal-title":"Clin Infect Dis"},{"key":"10.1053\/j.seminhematol.2024.08.002_bib0113","unstructured":"Infectious Diseases Society of America. IDSA and AMP joint statement on the use of SARS-CoV-2 PCR cycle threshold (Ct) values for clinical decision-making. https:\/\/www.idsociety.org\/globalassets\/idsa\/public-health\/covid-19\/idsa-amp-statement.pdf. [accessed 29.05.24]."},{"issue":"2","key":"10.1053\/j.seminhematol.2024.08.002_bib0114","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1093\/cid\/ciab394","article-title":"SARS-CoV-2 RNAemia predicts clinical deterioration and extrapulmonary complications from COVID-19","volume":"74","author":"Ram-Mohan","year":"2022","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.1053\/j.seminhematol.2024.08.002_bib0115","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1093\/infdis\/jiae198","article-title":"SARS-CoV-2 RNA and nucleocapsid antigen are blood biomarkers associated with severe disease outcomes that improve in response to remdesivir","volume":"230","author":"Singh","year":"2024","journal-title":"J Infect Dis"},{"issue":"10","key":"10.1053\/j.seminhematol.2024.08.002_bib0116","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.1093\/cid\/ciaa721","article-title":"Neutralizing antibody responses to severe acute respiratory syndrome coronavirus 2 in coronavirus disease 2019 inpatients and convalescent patients","volume":"71","author":"Wang","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1053\/j.seminhematol.2024.08.002_bib0117","unstructured":"Food and Drug Administration. Fact sheet for health care providers: emergency use authorization (EUA) of COVID-19 convalescent plasma for treatment of coronavirus disease 2019 (COVID-19) [accessed 29.05.24]. 2021."},{"issue":"10289","key":"10.1053\/j.seminhematol.2024.08.002_bib0118","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1016\/S0140-6736(21)00897-7","article-title":"Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial","volume":"397","year":"2021","journal-title":"Lancet"},{"issue":"11","key":"10.1053\/j.seminhematol.2024.08.002_bib0119","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1038\/s41591-021-01488-2","article-title":"Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial","volume":"27","author":"B\u00e9gin","year":"2021","journal-title":"Nat Med"},{"issue":"17","key":"10.1053\/j.seminhematol.2024.08.002_bib0120","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1001\/jama.2021.18178","article-title":"Effect of convalescent plasma on organ support-free days in critically Ill patients with COVID-19: a randomized clinical trial","volume":"326","author":"Estcourt","year":"2021","journal-title":"Jama"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.08.002_bib0121","doi-asserted-by":"crossref","DOI":"10.1136\/bmjmed-2022-000427","article-title":"Use of covid-19 convalescent plasma to treat patients admitted to hospital for covid-19 with or without underlying immunodeficiency: open label, randomised clinical trial","volume":"2","author":"Lacombe","year":"2023","journal-title":"BMJ Med"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.08.002_bib0122","first-page":"96","article-title":"Anti-SARS-CoV-2 antibody-containing plasma improves outcome in patients with hematologic or solid cancer and severe COVID-19: a randomized clinical trial","volume":"4","author":"Denkinger","year":"2023","journal-title":"Nature Cancer"},{"issue":"9","key":"10.1053\/j.seminhematol.2024.08.002_bib0123","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.eimc.2021.01.013","article-title":"Treatment of COVID-19 with convalescent plasma in patients with humoral immunodeficiency - Three consecutive cases and review of the literature","volume":"40","author":"Delgado-Fern\u00e1ndez","year":"2021","journal-title":"Enferm Infecc Microbiol Clin (Engl Ed)"},{"issue":"4","key":"10.1053\/j.seminhematol.2024.08.002_bib0124","doi-asserted-by":"crossref","first-page":"e138","DOI":"10.1016\/S2666-5247(21)00030-6","article-title":"Potential benefit of convalescent plasma transfusions in immunocompromised patients with COVID-19","volume":"2","author":"Rodionov","year":"2021","journal-title":"Lancet Microbe"},{"issue":"3","key":"10.1053\/j.seminhematol.2024.08.002_bib0125","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1111\/trf.17737","article-title":"Charting a path forward: promising outcomes of convalescent plasma therapy in the care of severely B-cell depleted patients with persistent COVID-19","volume":"64","author":"Inbar","year":"2024","journal-title":"Transfusion"},{"issue":"20","key":"10.1053\/j.seminhematol.2024.08.002_bib0126","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1182\/blood.2020008423","article-title":"Convalescent plasma therapy for B-cell-depleted patients with protracted COVID-19","volume":"136","author":"Hueso","year":"2020","journal-title":"Blood"},{"issue":"7","key":"10.1053\/j.seminhematol.2024.08.002_bib0127","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1056\/NEJMoa2033700","article-title":"Early high-titer plasma therapy to prevent severe Covid-19 in older adults","volume":"384","author":"Libster","year":"2021","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1053\/j.seminhematol.2024.08.002_bib0128","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1080\/14787210.2022.2098112","article-title":"The effect of intravenous immunoglobulins on the outcomes of patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials","volume":"20","author":"Lai","year":"2022","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"8","key":"10.1053\/j.seminhematol.2024.08.002_bib0129","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaip.2023.05.005","article-title":"Detection of SARS-CoV-2 antibodies in immunoglobulin products","volume":"11","author":"Cousins","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1053\/j.seminhematol.2024.08.002_bib0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijid.2024.107046","article-title":"Intravenous immunoglobulin therapy for COVID-19 in immunocompromised patients: a retrospective cohort study","volume":"144","author":"Gr\u00f6ning","year":"2024","journal-title":"Int J Infect Dis"},{"issue":"10","key":"10.1053\/j.seminhematol.2024.08.002_bib0131","doi-asserted-by":"crossref","first-page":"e810","DOI":"10.1016\/j.clml.2021.07.004","article-title":"Resolution of one-year persisting COVID-19 pneumonia and development of immune thrombocytopenia in a follicular lymphoma patient with preceding rituximab maintenance therapy: a follow-up report and literature review of cases with prolonged infections","volume":"21","author":"Yasuda","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"11","key":"10.1053\/j.seminhematol.2024.08.002_bib0132","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofab217","article-title":"The longest persistence of viable SARS-CoV-2 with recurrence of viremia and relapsing symptomatic COVID-19 in an immunocompromised patient\u2014a case study","volume":"8","author":"Sepulcri","year":"2021","journal-title":"Open Forum Infectious Diseases"},{"key":"10.1053\/j.seminhematol.2024.08.002_bib0133","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ijid.2023.09.021","article-title":"Antiviral combination therapies for persistent COVID-19 in immunocompromised patients","volume":"137","author":"Focosi","year":"2023","journal-title":"Int J Infect Dis"},{"issue":"7904","key":"10.1053\/j.seminhematol.2024.08.002_bib0134","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1038\/s41586-022-04482-x","article-title":"Pyrimidine inhibitors synergize with nucleoside analogues to block SARS-CoV-2","volume":"604","author":"Schultz","year":"2022","journal-title":"Nature"},{"key":"10.1053\/j.seminhematol.2024.08.002_bib0135","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.706431","article-title":"Successful chimeric antigen receptor (CAR) T-Cell treatment in aggressive lymphoma despite coronavirus disease 2019 (CoVID-19) and prolonged severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) replication - case report","volume":"11","author":"Nilius-Eliliwi","year":"2021","journal-title":"Front Oncol"},{"issue":"4","key":"10.1053\/j.seminhematol.2024.08.002_bib0136","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/s12185-024-03711-5","article-title":"Chimeric antigen receptor T-cell therapy after COVID-19 in refractory high-grade B-cell lymphoma","volume":"119","author":"Hayashino","year":"2024","journal-title":"Int J Hematol"},{"issue":"31","key":"10.1053\/j.seminhematol.2024.08.002_bib0137","doi-asserted-by":"crossref","first-page":"3547","DOI":"10.1200\/JCO.2017.73.0655","article-title":"Off-the-shelf virus-specific T Cells to treat BK virus, human herpesvirus 6, cytomegalovirus, epstein-barr virus, and adenovirus infections after allogeneic hematopoietic stem-cell transplantation","volume":"35","author":"Tzannou","year":"2017","journal-title":"J Clin Oncol"},{"issue":"26","key":"10.1053\/j.seminhematol.2024.08.002_bib0138","doi-asserted-by":"crossref","first-page":"5113","DOI":"10.1182\/blood-2013-02-486324","article-title":"Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation","volume":"121","author":"Leen","year":"2013","journal-title":"Blood"},{"issue":"8","key":"10.1053\/j.seminhematol.2024.08.002_bib0139","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1038\/s41591-023-02480-8","article-title":"SARS-CoV-2-specific T cell therapy for severe COVID-19: a randomized phase 1\/2 trial","volume":"29","author":"Papadopoulou","year":"2023","journal-title":"Nat Med"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.08.002_bib0140","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jcyt.2023.10.002","article-title":"Results of phase 2 randomized multi-center study to evaluate the safety and efficacy of infusion of memory T cells as adoptive therapy in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pneumonia and\/or lymphopenia (RELEASE NCT04578210)","volume":"26","author":"Ferreras","year":"2024","journal-title":"Cytotherapy"},{"issue":"10435","key":"10.1053\/j.seminhematol.2024.08.002_bib0141","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1016\/S0140-6736(24)00319-2","article-title":"Afamitresgene autoleucel for advanced synovial sarcoma and myxoid round cell liposarcoma (SPEARHEAD-1): an international, open-label, phase 2 trial","volume":"403","author":"D'Angelo","year":"2024","journal-title":"Lancet"},{"issue":"4","key":"10.1053\/j.seminhematol.2024.08.002_bib0142","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa2303379","article-title":"Cilta-cel or standard care in lenalidomide-refractory multiple myeloma","volume":"389","author":"San-Miguel","year":"2023","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1053\/j.seminhematol.2024.08.002_bib0143","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","article-title":"Ide-cel or standard regimens in relapsed and refractory multiple myeloma","volume":"388","author":"Rodriguez-Otero","year":"2023","journal-title":"N Engl J Med"},{"issue":"10343","key":"10.1053\/j.seminhematol.2024.08.002_bib0144","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1016\/S0140-6736(22)00662-6","volume":"399","author":"Kamdar","year":"2022","journal-title":"Lancet"},{"issue":"7","key":"10.1053\/j.seminhematol.2024.08.002_bib0145","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJMoa2116596","article-title":"Second-line tisagenlecleucel or standard care in aggressive B-Cell lymphoma","volume":"386","author":"Bishop","year":"2022","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1053\/j.seminhematol.2024.08.002_bib0146","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/s41591-021-01622-0","article-title":"Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial","volume":"28","author":"Fowler","year":"2022","journal-title":"Nat Med"},{"issue":"17","key":"10.1053\/j.seminhematol.2024.08.002_bib0147","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1182\/blood.2023021567","article-title":"Durable response after tisagenlecleucel in adults with relapsed\/refractory follicular lymphoma: ELARA trial update","volume":"143","author":"Dreyling","year":"2024","journal-title":"Blood"},{"issue":"7","key":"10.1053\/j.seminhematol.2024.08.002_bib0148","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene ciloleucel as second-line therapy for large B-Cell lymphoma","volume":"386","author":"Locke","year":"2022","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1053\/j.seminhematol.2024.08.002_bib0149","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1056\/NEJMoa2301665","article-title":"Survival with axicabtagene ciloleucel in large B-Cell lymphoma","volume":"389","author":"Westin","year":"2023","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.08.002_bib0150","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S1470-2045(21)00591-X","article-title":"Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial","volume":"23","author":"Jacobson","year":"2022","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1053\/j.seminhematol.2024.08.002_bib0151","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1182\/blood.2023021243","article-title":"Three-year follow-up analysis of axicabtagene ciloleucel in relapsed\/refractory indolent non-Hodgkin lymphoma (ZUMA-5)","volume":"143","author":"Neelapu","year":"2024","journal-title":"Blood"},{"issue":"10299","key":"10.1053\/j.seminhematol.2024.08.002_bib0152","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0140-6736(21)01222-8","article-title":"KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study","volume":"398","author":"Shah","year":"2021","journal-title":"Lancet"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.08.002_bib0153","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1186\/s13045-022-01379-0","article-title":"Two-year follow-up of KTE-X19 in patients with relapsed or refractory adult B-cell acute lymphoblastic leukemia in ZUMA-3 and its contextualization with SCHOLAR-3, an external historical control study","volume":"15","author":"Shah","year":"2022","journal-title":"J Hematol Oncol"}],"container-title":["Seminars in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196324000908?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196324000908?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,21]],"date-time":"2024-10-21T04:29:46Z","timestamp":1729484986000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0037196324000908"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":153,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S0037196324000908"],"URL":"https:\/\/doi.org\/10.1053\/j.seminhematol.2024.08.002","relation":{},"ISSN":["0037-1963"],"issn-type":[{"value":"0037-1963","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The winding road: Infectious disease considerations for CAR-T and other novel adoptive cellular therapies in the era of COVID-19","name":"articletitle","label":"Article Title"},{"value":"Seminars in Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminhematol.2024.08.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}